» Articles » PMID: 31077946

Anti-Claudin-1 Conjugated to a Near-Infrared Fluorophore Targets Colon Cancer in PDOX Mouse Models

Overview
Journal J Surg Res
Specialty General Surgery
Date 2019 May 12
PMID 31077946
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Claudins are tight-junction proteins, which maintain an epithelial barrier in normal colon cells. Overexpression of Claudin-1 has been implicated for development of colon cancer. We postulated that Claudin-1 may be a useful target in near-infrared imaging and fluorescence-guided surgery.

Methods: We conjugated Claudin-1 antibody to LI-COR IR800DyeCW (Claudin-1-IRDye800CW). Western blotting of 9 human colon cancer cell lysates was performed. Animal imaging was performed with the LI-COR Pearl Trilogy Fluorescence Imaging System. A dose-response study was carried out with subcutaneous LS174T colon cancer cell line models. Increasing doses of Claudin-1-IRDye800CW via tail vein injection were administered to three groups of mice. Two groups of mice were used as controls (antibody alone, and dye alone). In vivo imaging was performed at 24, 48, and 72 h after administration of the conjugated dye. Orthotopic implantation of patient-derived tumors and cell lines was performed and peritoneal carcinomatosis models were created. After tumor growth, mice were administered Claudin-1-IRDye800CW and imaged in vivo 48 h later. The mice were euthanized and laparotomy was performed to assess internal organs and toxicity.

Results: Western blotting revealed that all colon cancer cell lysates expressed varying amounts of Claudin-1. All tumors demonstrated strong and specific fluorescence labeling at 800 nm, even with the lowest dose of 12.5 μg of Claudin-1-IRDye800CW.

Conclusions: Claudin-1 is a useful target for near-infrared antibody-based imaging for visualization of colorectal tumors for future use in fluorescence-guided surgery.

Citing Articles

The Expression of the Claudin Family of Proteins in Colorectal Cancer.

Cox K, Liu S, Hoffman R, Batra S, Dhawan P, Bouvet M Biomolecules. 2024; 14(3).

PMID: 38540693 PMC: 10967842. DOI: 10.3390/biom14030272.


Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models.

Cox K, Turner M, Amirfakhri S, Lwin T, Hosseini M, Ghosh P J Surg Res. 2023; 293:701-708.

PMID: 37839102 PMC: 11060874. DOI: 10.1016/j.jss.2023.08.038.


Expression of Claudins in Preneoplastic Conditions of the Gastrointestinal Tract: A Review.

Ouban A, Arabi T Cancers (Basel). 2023; 15(16).

PMID: 37627123 PMC: 10452390. DOI: 10.3390/cancers15164095.


Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study.

Turner M, Cox K, Neel N, Amirfakhri S, Nishino H, Clary B J Pers Med. 2023; 13(5).

PMID: 37241027 PMC: 10221372. DOI: 10.3390/jpm13050857.


Intestinal Barrier, Claudins and Mycotoxins.

Koziel M, Ziaja M, Piastowska-Ciesielska A Toxins (Basel). 2021; 13(11).

PMID: 34822542 PMC: 8622050. DOI: 10.3390/toxins13110758.


References
1.
Hoffman R . Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015; 15(8):451-2. DOI: 10.1038/nrc3972. View

2.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

3.
Dhawan P, Singh A, Deane N, No Y, Shiou S, Schmidt C . Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005; 115(7):1765-76. PMC: 1150288. DOI: 10.1172/JCI24543. View

4.
Orosco R, Tapia V, Califano J, Clary B, Cohen E, Kane C . Positive Surgical Margins in the 10 Most Common Solid Cancers. Sci Rep. 2018; 8(1):5686. PMC: 5890246. DOI: 10.1038/s41598-018-23403-5. View

5.
Rabinsky E, Joshi B, Pant A, Zhou J, Duan X, Smith A . Overexpressed Claudin-1 Can Be Visualized Endoscopically in Colonic Adenomas In Vivo. Cell Mol Gastroenterol Hepatol. 2016; 2(2):222-237. PMC: 4980721. DOI: 10.1016/j.jcmgh.2015.12.001. View